Dr. Elias J. Jabbour     CML      Chronic Myeloid Leukemia    

Assistant Professor, Department of Leukemia,
Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX

VIDEOS

Meet leukemia oncologist Elias Jabbour, M.D.
December 7, 2021, MD Anderson Cancer Center

Omacetaxine: Old Drug With New Uses
April 14, 2015, OncLiveTV

How I treat CML Elias Jabbour
April 1, 2014,  TheMedalGroup

CML prognostication and response/ when to do molecular mutational analysis? ELias Jabbour
April 1, 2014, TheMedalGroup

Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
February 24, 2014, OncLiveTV

HEM-ONC CHAT: Dr. Elias Jabbour, 'Treatment a la Carte in CML'
December 11, 2012, MDedge

CML Update at ASH 2011 - Interview with Elias Jabbour, M.D.                
January 27, 2012, OncUViewTV

Dr. Jabbour on Front-Line Treatments for CML                                               
March 15, 2011, OncLiveTV

Dr. Jabbour on Second-Generation TKIs in CML                                  
March 15, 2011, OncLiveTV

ARTICLES

Jabbour Reviews TKI Options in Case Study of Chronic Phase CML
March 21, 2019, Targeted Oncology

Expert Insights: CML Updates From Summer 2011
August 17, 2011, Medscape education

Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 4, 2011, Online Library

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
February 10, 2011, Journal Blood

Tyrosine Kinase Inhibitors in CML: Applying New Data to Practice -- An Expert Interview
With Dr. Elias J. Jabbour From ASH 2009
2009, Medscape Education

  
​                                                    See also CML Experts in USA
​